FDA FLOATS LEGISLATIVE AGENDA ON CAPITOL HILL; AGENCY SEEKS REDEFINITION OF CLASS II AS "SAFETY AND PERFORMANCE" CATEGORY, DEEMPHASIZING SUBSTANTIAL EQUIVALENCE
This article was originally published in The Gray Sheet
Executive Summary
An FDA "wish list" of device legislative concepts seeks to redefine Class II as a category focused on "safety and performance" rather than "substantial equivalence."